-
Autoimmune hepatitis — Comprehensive overview covers symptoms, complications, treatment and risk factors of this liver disease.
MayoClinic.com (Epatologia) - Lun, 1 Marzo 2010
http://www.mayoclinic.com
-
There are no known case reports of hepatic steatosis caused by oral fluoropyrimidines such as capecitabine. With increasing use of capecitabine since its approval for the treatment of metastatic colon cancer in 2001, and more recently for adjuvant treatment of colon cancer and treatment of metastatic breast cancer, we can anticipate increased recognition of potential toxicities associated with this 5-fluorouracil derivative.Case presentationWe report the case of a 74-year-old woman who received capecitabine as adjuvant treatment for colon cancer and subsequently developed abnormal liver biochemical tests and radiographic findings in keeping with hepatic steatosis. There was complete reversal of liver enzyme abnormalities with discontinuation of the drug and this patient represents a case of reversible liver injury due to capecitabine. Conclusion: In this original case report, capecitabine use was associated with hepatic steatosis. It is important for clinicians to recognize and monitor for this potential toxicity, which may be a cause of abnormal liver enzymes in this patient population.
BioMed Central (Epatologia) - Ven, 12 Febbraio 2010
http://www.biomedcentral.com
-
Hepatitis B and hepatitis C viruses are common, infecting about 500 million people worldwide. Often asymptomatic, the disease might not be noticed until complications, such as hepatocellular carcinoma, develop. Hepatitis B can be prevented by vaccination, and simple precautions reduce infection from both viruses. But this knowledge has not been translated into decreased incidence in the USA. The Institute of Medicine investigated why not in Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C published on Jan 11.
The Lancet (Epatologia) - Ven, 22 Gennaio 2010
http://www.thelancet.com
-
More than 7000 delegates attended the 60th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, USA (Oct 30 to Nov 3) to share the latest findings on the pathology and treatment of liver disease. We report some of the major advances in hepatitis B (HBV) and hepatitis C (HCV).
The Lancet Infectious Diseases (Epatologia) - Gio, 7 Gennaio 2010
http://www.thelancet.com/journals/laninf
-
Hepatocellular carcinoma is the third most common cause of cancer related mortality worldwide, and in the United Kingdom population data show that age standardised incidence rose from 1.4 to 3.9 per 100 000 people between 1975 and 2006 (http://info.cancerresearchuk.org/cancerstats/types/liver). Cirrhosis of the liver is the strongest predisposing factor—80-90% of cases arise from chronic liver disease. Furthermore, in cohort studies of patients with cirrhosis, hepatocellular carcinoma is the leading cause of liver related death.
British Medical Journal (Epatologia) - Ven, 11 Dicembre 2009
http://www.bmjjournals.com
-
Although neomycin has been used to treat hepatic encephalopathy for many years, no controlled studies have found it to be effective, as compared with standard treatment alone.
New England Journal of Medicine (Epatologia) - Ven, 9 Ottobre 2009
http://www.nejm.org
-
More than seventy percent of people who contract Hepatitis C will live with the virus that causes it for the rest of their lives and some will develop serious liver disease including cancer. However, 30 to 40 percent of those infected somehow defeat the infection and get rid of the virus with no treatment. In this week’s Advanced Online Publication atNature, Johns Hopkins researchers working as part of an international team report the discovery of the strongest genetic alteration associated with the ability to get rid of the infection.
Johns Hopkins Hospital (Epatologia) - Ven, 18 Settembre 2009
http://www.hopkinshospital.org
-
Hepatitis C — Comprehensive overview covers symptoms, treatment of infection with the hepatitis C virus.
MayoClinic.com (Epatologia) - Lun, 14 Settembre 2009
http://www.mayoclinic.com
-
Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.
Johns Hopkins Hospital (Epatologia) - Lun, 27 Luglio 2009
http://www.hopkinshospital.org
-
Liver cancer — Comprehensive overview covers symptoms and treatment of this cancer, including hepatocellular carcinoma.
MayoClinic.com (Epatologia) - Ven, 3 Luglio 2009
http://www.mayoclinic.com